Healthy VolunteersPTSDMDMA

The effect of MDMA on anterior pituitary hormones: a secondary analysis of a randomized placebo-controlled trial

In a double‑blind, placebo‑controlled, randomised crossover trial of 15 healthy adults, a single 100 mg oral dose of MDMA acutely and robustly activated the HPA axis, producing significant increases in plasma ACTH and cortisol. Together with its known effect on oxytocin, this suggests MDMA could serve as a novel simultaneous stimulation test for oxytocin and HPA axis function, pending validation in larger studies.

Authors

  • Matthias Liechti

Published

Endocrine Connections
individual Study

Abstract

Background 3,4-Methylenedioxymethamphetamine (MDMA), a psychoactive substance, has been proposed as a novel provocation test for oxytocin deficiency. Limited evidence suggests that MDMA may also stimulate the anterior pituitary. Therefore, this analysis aimed to investigate the acute effect of MDMA on the anterior pituitary in healthy adults.

Methods

This secondary analysis utilized data from a double-blind, placebo-controlled, crossover, randomized trial. Healthy participants received a single oral dose of MDMA (100 mg) or placebo in random order. Plasma hormone levels of the anterior pituitary (adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), luteinizing hormone (LH), prolactin, growth hormone (GH)) and their peripheral endocrine glands (cortisol, free thyroxine (fT4), testosterone, and estradiol) were measured at baseline and 120 min after drug-intake. Plasma hormone changes following MDMA vs placebo were compared using the paired Wilcoxon test.

Results

Fifteen healthy participants (median (IQR) age: 35 years (26, 48); 53% female) with a mean (SD) BMI of 23.2 kg/m2 (2.1) were included. MDMA stimulated the hypothalamic–pituitary–adrenal (HPA) axis, with plasma ACTH increasing from 12 ng/L (11, 15) at baseline to 38 ng/L (25, 59) at 120 min, resulting in a significant change of ACTH (P < 0.001). This was accompanied by a cortisol increase from 347 nmol/L (252, 409) to 566 nmol/L (457, 701), resulting in a significant change of cortisol (P = 0.006). Prolactin showed a mild change of 4 μg/L (−1, 12) (P = 0.062). No effects of MDMA were observed on the remaining anterior pituitary axes.

Conclusion

MDMA strongly activates the HPA axis, in addition to stimulating oxytocin, suggesting that MDMA may serve as a novel stimulation test for assessing the two pituitary axes simultaneously. Further validation in larger patient populations is necessary.

Available with Blossom Pro

Research Summary of 'The effect of MDMA on anterior pituitary hormones: a secondary analysis of a randomized placebo-controlled trial'

Introduction

MDMA (3,4-methylenedioxymethamphetamine) is a psychoactive compound studied both recreationally and as a potential treatment for post-traumatic stress disorder. Prior animal and human work shows a robust MDMA-induced release of oxytocin from the posterior pituitary; animal studies also report stimulatory effects on anterior pituitary axes, including increases in ACTH, cortisol, TSH, thyroxine and prolactin. Human data, however, are limited and inconsistent: cortisol rises after MDMA are well documented, but whether ACTH and other anterior pituitary hormones are directly stimulated in humans remains uncertain, and no clear human data exist for pituitary-thyroid effects. Diagnosing hypopituitarism typically relies on basal measures and dynamic provocation tests, which are resource-intensive, so a single agent able to stimulate multiple pituitary axes could have diagnostic utility. Atila and colleagues performed a secondary analysis of data from a randomized, double-blind, placebo-controlled, crossover trial to test whether a single 100 mg oral dose of MDMA acutely stimulates anterior pituitary hormones in healthy adults. They hypothesised that, in addition to oxytocin, MDMA would increase secretion across multiple anterior pituitary axes and explored correlations between hormonal changes and cardiovascular and subjective psychoactive effects.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

See Pro PlansAlready have an account? Sign in

Full Text PDF

Full Paper PDF

Pro members can view the original manuscript directly in the browser.

See Pro PlansAlready have an account? Sign in
Open PDF in new tab

Study Details

  • Study Type
    individual
  • Journal
    Endocrine Connections
  • Compound
    MDMA
  • Topics
    Healthy VolunteersPTSD
  • Author
    Matthias Liechti
  • APA Citation

    Atila, C., Camerin, S., Liechti, M. E., & Christ-Crain, M. (2025). The effect of MDMA on anterior pituitary hormones: a secondary analysis of a randomized placebo-controlled trial. Endocrine Connections, 14(6). https://doi.org/10.1530/ec-25-0254

References (3)

Papers cited by this study that are also in Blossom

Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial

Atila, C., Christ-Crain, M., Liechti, M. E. et al. · Lancet Diabetes Endocrinol (2023)

Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants

Straumann, I., Avedisian, I., Klaiber, A. et al. · Neuropsychopharmacology (2024)

11 cited
MDMA enhances emotional empathy and prosocial behavior

´dric, C., Hysek, M., Schmid, Y. et al. · Social Cognitive and Affective Neuroscience (2013)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

See Pro PlansSign in